Faruque et al. [18] used 11 different VEGF inhibitors, namely, axitinib, bevacizumab, sunitinib, sorafenib, vandetanib, neovastat, cediranib, pazopanib, IM 862, PTK/ZA, and motesanib, for patients with different types of cancer and reported that the use of VEGF inhibitors potentially increased the risk of important adverse effects, such as myocardial infarction, arterial thromboembolism, hypertension, and new proteinuria, in patients with cancer. The gene discussed is VEGFA; the disease is hypertensive disorder.